Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Medicine Center of Excellence, |
RCV000171204 | SCV000221401 | likely pathogenic | not provided | criteria provided, single submitter | research | ||
Labcorp Genetics |
RCV001320102 | SCV001510875 | likely benign | Long QT syndrome | 2024-04-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003165352 | SCV003896211 | uncertain significance | Cardiovascular phenotype | 2022-11-03 | criteria provided, single submitter | clinical testing | The p.D57N variant (also known as c.169G>A), located in coding exon 2 of the CACNA1C gene, results from a G to A substitution at nucleotide position 169. The aspartic acid at codon 57 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |